Is jnj a good long-term investment? (2024)

Is jnj a good long-term investment?

The financial health and growth prospects of JNJ, demonstrate its potential to perform inline with the market. It currently has a Growth Score of D. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.

Is Johnson and Johnson stock good for long-term?

With its impressive history of dividend growth and a current yield of 3.2%, income-oriented investors have reason to be optimistic about the stock's long-term potential.

Is JNJ a safe investment?

Johnson & Johnson is a safe investment option with a history of consistent income and extreme financial safety. JNJ's recent performance, positive business developments, and long-term growth prospects make it a compelling investment for conservative investors.

What will JNJ stock be worth in 5 years?

Johnson & Johnson stock price stood at $159.81

According to the latest long-term forecast, Johnson & Johnson price will hit $200 by the end of 2026 and then $250 by the end of 2028. Johnson & Johnson will rise to $300 within the year of 2030 and $350 in 2033.

What is the future of JNJ?

J&J expects to grow operational sales by 5%-7% through 2027. Notably, it anticipates a third of its sales to come from new products in 2027. The company set 2024 sales growth forecasts for between 5%-6%. It expects adjusted earnings per share to range between $10.55 and $10.75.

Is JNJ dividend safe?

Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Johnson & Johnson paid out 92% of its earnings, which is more than we're comfortable with, unless there are mitigating circ*mstances.

What are the safest stocks to buy long term?

Is JNJ in trouble?

J&J has been sued by thousands of plaintiffs who claim its talcum powder caused them to develop cancer because it contained asbestos. The company planned to handle them by letting a new subsidiary, LTL Management, assume liabilities and declare bankruptcy.

Why is JNJ stock so low?

The sprawling litigation over its talc products, in particular, took a turn for the worse in late July. Still, much of the drop likely stems from a broader malaise that's afflicted pharmaceutical and medical device stocks this year. More than one malady has struck the healthcare sector, and there's no panacea in sight.

Which is better to invest in Pfizer or Johnson and Johnson?

JNJ's product pipeline in the Pharmaceutical segment has more late-stage developments, supporting its positive growth outlook. Pfizer has a stronger financial position for future M&A activities, but JNJ's acquisitions are more diversified and provide potential synergies.

Is JNJ overvalued or undervalued?

The stock looks slightly undervalued, as the market is likely not fully appreciating the firm's long-term potential with pipeline products that also reinforce J&J's wide moat.

What are analysts saying about JNJ stock?

Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $178.08 with a high estimate of $215 and a low estimate of $160.

What will JNJ stock price be in 2025?

What is the weakness of JNJ?

Weaknesses. Product recalls: The company has faced several product recalls, which have impacted its reputation and financial performance. Litigation risks: The company faces potential litigation risks from product liability lawsuits and government investigations, which can result in high costs and damage its reputation ...

Will JNJ stock recover?

We estimate Johnson & Johnson's Valuation to be $159 per share, reflecting only a 5% upside from its current levels of $151. Our forecast is based on a 15x P/E multiple for JNJ and expected earnings of $10.13 on a per-share and adjusted basis for the full year 2023.

Is JNJ going to split into two companies?

Why Johnson & Johnson is splitting itself into two publicly traded companies. Johnson & Johnson, the biggest pharmaceutical company in the U.S. based on market cap, announced in November 2021 it plans to spin off its consumer business into a new publicly traded company by November 2023.

What is the safest dividend stock to buy now?

Kinder Morgan (NYSE: KMI), Equinix (NASDAQ: EQIX), and Lockheed Martin (NYSE: LMT) are three super-safe dividend stocks because they generate contractually secured cash flow and have strong financial profiles. That makes them great options for those seeking to fortify their dividend income in 2024 and beyond.

Is Johnson and Johnson undervalued?

The GF Value Line provides an overview of the fair value at which the stock should ideally be traded. According to our valuation method, Johnson & Johnson's stock appears to be modestly undervalued. If the stock price is significantly above the GF Value Line, it may be overvalued, indicating poor future returns.

Does JNJ pay monthly dividends?

Johnson & Johnson's ( JNJ ) ex-dividend date is February 16, 2024 , which means that buyers purchasing shares on or after that date will not be eligible to receive the next dividend payment. Johnson & Johnson ( JNJ ) pays dividends on a quarterly basis. The next dividend payment is planned on March 5, 2024 .

What stocks will boom in 2024?

Is it smart to invest in VOO?

What do analysts say about VOO? VOO's analyst rating consensus is a Moderate Buy. This is based on the ratings of 505 Wall Streets Analysts.

What are the three stocks you can keep forever?

Is J&J in bankruptcies?

J&J has a net value of hundreds of billions of dollars. Despite this, J&J filed for bankruptcy in 2021 using a controversial legal maneuver called the “Texas Two-Step.” The two steps are: Step 1: Create an underfunded subsidiary company and offload asbestos liabilities into it.

What is the JNJ controversy?

Tens of thousands of plaintiffs have sued, alleging that J&J's baby powder and other talc products sometimes contained asbestos and caused ovarian cancer and mesothelioma.

Why is JNJ being sued?

NEW YORK, Dec 29 (Reuters) - A federal judge said Johnson & Johnson (JNJ. N) shareholders may pursue as a class action their lawsuit accusing the company of fraudulently concealing how its talc products were contaminated by cancer-causing asbestos.